Roche launches first AI-enabled continuous glucose monitor in the Middle East, offering people with diabetes two-hour and overnight predictive notifications

• The Accu-Chek® SmartGuide continuous glucose monitoring (CGM) solution provides 14 days accurate real-time glucose values for adults living with diabetes1

• Artificial intelligence (AI)-enabled algorithms can predict glucose levels up to two hours ahead and overnight, empowering users to proactively take an action before an glucose excursion occurs2

• With over 85 million adults across the Middle East and North Africa region living with diabetes3 , the roll out of the Accu-Chek SmartGuide® CGM solution has the potential to transform diabetes care in the region

Middle East, 13 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its Accu-Chek® SmartGuide continuous glucose monitoring (CGM) solution is now available in the Middle East - with the first role out in Kuwait, Qatar, KSA, and other markets to follow starting with UAE in the very near future. This significant milestone means that people living with diabetes over the age of 18 can now benefit from the solution’s enhanced glucose monitoring and artificial intelligence (AI)-enabled predictive insights.1,2

Diabetes is one of today’s most urgent healthcare challenges. Across the Middle East and North Africa (MENA) region, 85 million people are living with the condition.3 If left unmanaged, diabetes can lead to secondary complications including cardiovascular disease, kidney disease, nerve damage, blindness, lower limb amputation and mental health issues.4

“Across the Middle East, where diabetes continues to impact millions and prevalence is rising, equipping people with the tools and confidence to manage their own health is a vital step towards creating healthier populations. By empowering people to manage the condition through our AI-powered predictive technology, we are confident that this can change the course of this condition for our patients.” said Guido Sander, General Manager, Roche Diagnostics Middle East.

“With CGM and our innovative digital solutions we support the healthcare ecosystems in the Middle East in becoming proactive, data-driven, and patient focussed.”

Since it was introduced, CGM technology has significantly improved diabetes care,5 yet a significant number of people still have difficulty keeping their glucose in the right range when using current systems.6 Hypoglycemia is common amongst persons who have type 1 diabetes, with an annual incidence of severe hypoglycemia ranging from 3.3% to 13.5%.7

Nighttime hypoglycemia can present a particular challenge for people with diabetes. Approximately 2-5% of deaths in people with type 1 diabetes under the age of 40 are due to episodes of very low glucose during the night.8,9 The unpleasant symptoms and negative consequences of hypoglycemia can result in actual fear of hypoglycemia with possible significant implications for the diabetes management, metabolic control and subsequent health outcomes.10

The Accu-Chek SmartGuide CGM solution uses AI-enabled algorithms to predict where an individual’s glucose levels are likely headed in the next 30 minutes, two hours, and even overnight. This means people with diabetes can move from a reactive to a proactive approach to their daily management, preparing for and managing potential episodes in advance, rather than waiting for alerts when they happen.

The Accu-Chek SmartGuide CGM solution includes a wireless, water-resistant sensor, worn on the back of the upper arm, and the app, where the users can see their current glucose levels and their future glucose development through predictive analytics. Every five minutes, the sensor sends glucose values measured in real-time to the app. The app then uses those glucose values and other optional information entered by the user such as food intake and insulin doses to detect patterns and predict future glucose levels. Supported by AI-trained algorithms, it provides key predictions of likely hypoglycaemia within 30 minutes and suggests what can be done to keep glucose levels in range, as well as general estimated predictions of glucose levels within two hours and during a defined 7-hours nighttime period.11

Clinical studies have demonstrated the new Roche CGM solution's high system accuracy, with an overall mean absolute relative difference (MARD) of 9.2% and 99.8% of measured glucose values falling within zones A and B on the Parkes Error Grid.1,12 The evaluation of the predictive capabilities showed that all advanced predictive features exceeded high performance requirements as e.g. accuracy, sensitivity and specificity.13

About the Accu-Chek SmartGuide CGM solution

Accu-Chek SmartGuide is a continuous glucose monitoring (CGM) solution developed by Roche providing accurate1 real-time glucose readings and AI-enabled predictions for different timeframes.8 The solution includes three elements: the Accu-Chek SmartGuide CGM sensor, the Accu-Chek SmartGuide App and the Accu-Chek SmartGuide Predict App. With an all-in-one applicator and 14-day wear time, Accu-Chek SmartGuide is designed for people living with diabetes, 18 years of age and older. It aims at empowering people living with diabetes to be prepared for the future development of glucose levels and take preventive action by making the appropriate therapy adjustments in good time.

The Accu-Chek SmartGuide solution seamlessly integrates with the Accu-Chek® Care platform, offering healthcare professionals (HCPs) access to comprehensive and accurate1 therapy-relevant data provided by the CGM solution. This integration allows HCPs to analyse together with their patients how lifestyle and therapy impact their glucose levels and make more informed decisions.

About Roche

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In the Middle East, Roche Diagnostics offers comprehensive expertise through the relevant and appropriate channels in 14 countries: UAE, Saudi Arabia, Iraq, Iran, Qatar, Kuwait, Bahrain, Oman, Yemen, Syria, Jordan, Palestine, Lebanon,  and Maldives.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. 

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. 

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Local Media Relations

Asmaa Khalil

Head of Communication and Public Affairs Middle East, Roche Diagnostics LLC

Email: [email protected]